Digital Genome Market Report 2026

The digital genome market size has grown rapidly in recent years. It will grow from $46.82 billion in 2025 to $56.12 billion in 2026 at a compound annual growth rate (CAGR) of 19.9%. The growth in the historic period can be attributed to declining genome sequencing costs, expansion of genomics research programs, growth in inherited disease studies, limited data integration tools, academic research funding.

The digital genome market size is expected to see rapid growth in the next few years. It will grow to $115.83 billion in 2030 at a compound annual growth rate (CAGR) of 19.9%. The growth in the forecast period can be attributed to growth of personalized medicine, expansion of population genomics, ai-driven variant interpretation, increased healthcare genomics adoption, regulatory support for genomics. Major trends in the forecast period include rapid growth of genomic data digitization, increasing use of ai in genomic analysis, expansion of cloud-based genome data platforms, rising demand for precision medicine applications, integration of genomic data with clinical systems.

The increasing prevalence of genetic disorders is expected to drive the growth of the digital genome market in the coming years. Genetic disorders are inherited conditions caused by abnormalities or mutations in an individual’s DNA, which carries the instructions for normal growth and bodily functions. Digital genome technologies support the identification of genetic mutations and variations linked to these disorders, enabling accurate and early diagnosis. This early detection facilitates timely medical intervention and improved treatment outcomes. For instance, in August 2023, according to the National Library of Medicine, a US-based medical library, sickle cell anemia affects approximately 1 in 500 African Americans in the United States. Additionally, around 1 in 12 African Americans carries the autosomal recessive mutation responsible for the condition, and nearly 300,000 infants are born with sickle cell anemia each year worldwide. Therefore, the rising prevalence of genetic disorders is contributing to the growth of the digital genome market.

Major companies operating in the digital genome market are increasingly focused on adopting advanced sequencing approaches, such as high-throughput long-read sequencing technologies, to improve genomic accuracy, scalability, and data-generation efficiency. High-throughput long-read sequencing systems are next-generation platforms that use single-molecule real-time technology to generate long and highly accurate DNA reads, enabling comprehensive variant detection, real-time base calling, and large-scale whole-genome analysis. For instance, in March 2023, Pacific Biosciences of California Inc., a US-based life science sequencing technology company, launched the Revio System, a high-throughput long-read sequencing platform designed to deliver large volumes of high-fidelity genome data for population-scale genomics, epigenetics, and disease research. The system offers significantly higher data output per run, integrated deep-learning-based methylation detection, and reduced consumable usage, supporting faster, more accurate, and cost-efficient genomic analysis.

In January 2023, Agilent Technologies, a US-based analytical solutions company, acquired Avida Biomed for an undisclosed amount. Through this acquisition, Agilent Technologies aims to strengthen its next-generation sequencing capabilities by integrating Avida Biomed’s target enrichment workflows into its genomic solutions portfolio. Avida Biomed is a US-based life sciences company specializing in the development of advanced target enrichment workflows for next-generation sequencing applications.

Major companies operating in the digital genome market are Roche Holding AG, Thermo Fisher Scientific Inc., GE HealthCare Technologies Inc., Quest Diagnostics, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., bioMerieux SA, PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., BGI Genomics, Myriad Genetics Inc., Foundation Medicine Inc., ArcherDx Inc., Invitae Corporation, Oxford Nanopore Technologies Ltd., Luminex Corporation, GenMark Diagnostics Inc., NanoString Technologies Inc., Pacific Biosciences of California Inc., Genewiz, Inscripta Inc., Genomic Health Inc., Becton Dickinson and Company, GenomeMe, Regeneron Pharmaceuticals Inc.

North America was the largest region in the digital genome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital genome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital genome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the digital genome market by increasing costs of imported sequencing instruments, reagents, data servers, and analytical hardware. Research institutes and hospitals in developed regions are most affected due to reliance on imported genomic equipment, while emerging markets face higher infrastructure costs. These tariffs increase research expenses. However, they also promote domestic sequencing capabilities and local bioinformatics platform development.

The digital genome market research report is one of a series of new reports that provides digital genome market statistics, including digital genome industry global market size, regional shares, competitors with a digital genome market share, detailed digital genome market segments, market trends and opportunities, and any further data you may need to thrive in the digital genome industry. This digital genome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The digital genome refers to the digitized and structured representation of an organism’s genetic material, including DNA and RNA sequences. This digital format enables the storage, analysis, and interpretation of genetic information using computational tools and technologies, supporting deeper insights into genetic variation, disease mechanisms, and evolutionary relationships.

The main types of digital genome solutions include sequencing and analyzer instruments, and data analysis and management tools. Sequencing and analyzer instruments are used in genomic sequencing and analysis to decode genetic information from DNA and RNA molecules. These solutions are applied across areas such as diagnostics, agriculture and animal research, personalized medicine, drug discovery, and treatment analysis, and are used by research centers and government institutes, academic institutions, pharmaceutical and biotechnology companies, hospitals, and diagnostic centers.

The digital genome market consists of revenues earned by entities by providing services such as DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) isolation, profiling, qPCR, next-generation sequencing, and advanced bioinformatics data analysis pipelines. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital genome market also includes sales of sequencing and analyzer instruments, sequencing chips, sample preparation instruments, and sequencing and analysis software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.